Here’s the blurb………The 6th Edition of The European Cannabis Report takes an in-depth look at the progress of cannabis legalisation in the region, analysing trade, supply chains, commercial developments, medical products on the market and the patients who use them. It also considers how COVID-19 has affected the market in Europe and what this means for the year ahead.

We estimate that over 60,000 people were able to access cannabis medications for the first time in Europe during 2020, bringing the total to 185,000 patients accessing medical cannabis treatment in the region during the year. Overall, we estimate the value of the market for medical cannabis to be worth €230.7 million as of the end of 2020. Further, we expect the value of European cannabis to grow at a CAGR of 67.4%, to reach €3.2 billion in 2025.

Our exclusive consumer data from over 15,000 adults across seven international markets will allow you to dissect international regulations helping businesses, brands and investors to understand the future of the European cannabis market. Our approach to forecasting the European cannabis industry has its foundation in the database of historical data points (sales, patients, volumes, imports, prices etc.), available in Atalis.

KEY FINDINGS FROM THE REPORT INCLUDE:

  • The European cannabis market will be worth €403.4 million by the end of 2021. We expect the market to grow with a CAGR of 67.4% from 2021 to reach €3.2 billion by 2025.
  • We predict Germany will constitute over half of the European market until 2024 and will be worth over €840 million by the end of the forecast period.
  • By the end of 2025, we expect several nations to introduce legal access to adult-use cannabis including Netherlands, Switzerland, Germany and others. We estimate these sales could be worth over €500 million by 2025.
The European Cannabis Report: 6th Edition is available for free download now.